Figure 3. UACA expression is elevated in cancer tissues.

(A,B,C) Expression of UACA, p65/NF-κB, or GRP78 in normal and cancer tissues. Sections of normal prostate (n=20) or grade 1 prostate adenocarcinoma (n=24) (A,C); and normal lung (n=10), lung adenocarcinoma (n=38) or squamous cell lung carcinoma (n=39) (B,C); were subjected to IHC with either a control antibody or UACA antibody (A,B,C), p65/NF-κB antibody (C, left panel), or GRP78 antibody (C, right panel), using DAB (brown), and nuclei were counterstained blue with hematoxylin. As expected, no staining was observed with the control antibody (Figure S3A), and detection of UACA with the UACA antibody was neutralized by corresponding UACA peptide (Figure S3B). Representative sections are shown at 100X (A and B). UACA or GRP78 expression in the normal and cancer tissues was scored as ‘≤ 1+’, ‘2+’, or ‘≥ 3+’. Percentage of tissues co-expressing ‘nuclear p65 expression and high (‘≥ 3+’) UACA’ (C, left panel), or ‘nuclear p65 expression/high (‘≥ 3+’) UACA’ and ‘≤ 1+’, ‘2+’, or ‘≥ 3+’ levels of GRP78 (C, right panel) is shown.

(D) UACA up-regulation correlates with NF-κB activation. Western blot (WB) analysis was performed on lysates prepared from freshly frozen prostate cancer or lung cancer tissues and corresponding matched normal tissue controls.